Q1 2023 Results

Existing brands Company overview Innovation: Pipeline overview Financial review Financial performance Novartis submission schedule Supplementary indications for existing brands Conclusions Appendix Innovation: Clinical trials References Abbreviations INNOVATION Cardiovascular Immunology Neuroscience Solid tumors Hematology Non-core TA project KisqaliⓇ 2023 ribociclib, LEE011 HR+/HER2- BC (adj) LutatheraⓇ 177 Lu-oxodotreotide GEP-NET 1L G3 XolairⓇ omalizumab, IGE025 Food allergy PiqrayⓇ alpelisib, BYL719 Ovarian cancer denosumab BioS anti RANKL mAb GP2411 JakaviⓇ 2024 ruxolitinib, INC424 Pediatrics Acute GVHD. JakaviⓇ ruxolitinib, INC424 Pediatrics Chronic GVHD ScemblixⓇ ABL001 CML 1L Adakveo SEG101 Sickle cell disease, pediatrics aflibercept SOK583 BioS Neovascular age-related macular degeneration 2025 CosentyxⓇ secukinumab, AIN457 GCA LeqvioⓇ KJX839 Ped Hyperlipidemia ZolgensmaⓇ AVXS-101 OAV101 SMA IT BeovuⓇ brolucizumab, RTH258 Diabetic retinopathy PromactaⓇ eltrombopag, ETB115 Radiation sickness syndrome Coartem® artemether + lumefantrine, COA566 Malaria uncompl., formula for <5kg ty 1. 177 Lu-dotatate in US. 2. Kesimpta and Mayzent: Pediatric study in multiple sclerosis run in conjunction (NEOS). 40 Investor Relations | Q1 2023 Results AimovigⓇ erenumab, AMG334 Pediatric Migraine CosentyxⓇ secukinumab, AIN457 Lupus Nephritis CosentyxⓇ secukinumab, AIN457 Tendinopathy CosentyxⓇ secukinumab, AIN457 Polymyalgia rheumatica KesimptaⓇ2 ofatumumab Multiple sclerosis, pediatrics LeqvioⓇ KJX839 CVRR-LDLC ≥2026 LeqvioⓇ KJX839 Primary prevention MayzentⓇ2 siponimod, BAF312 Multiple sclerosis, pediatrics ty RydaptⓇ midostaurin, PKC412 Acute myeloid leukemia, pediatrics ScemblixⓇ ABL001 CML, 2L, pediatrics AtecturaⓇ indacaterol + mometasone, QMF149 Asthma, pediatrics NOVARTIS | Reimagining Medicine O

View entire presentation